Key result
Clinical cardiac sarcoidosis is linked to better outcomes than histological disease, primarily predicted by LVEF and VT.
Cohort (n=422)
Answers are grounded in this paper and cite their sources.
Diagnosis of cardiac sarcoidosis (CS) is sometimes difficult due to a low positive rate of epithelioid granulomas by endomyocardial biopsy (EMB). Accordingly, Japanese guidelines can allow the CS diagnosis using clinical data alone without EMB results (clinical CS) since 2006. However, little is known about prognosis and outcome of clinical CS. Purpose of this study was to analyze the prognosis, outcomes, and response to corticosteroid of clinical CS using large-scale cohort survey. Overall, 422 CS patients (mean age 60 ± 13 years, 68% female, median follow-up period of 5 years), including 345 clinical CS and 77 EMB-positive patients, histologically diagnosed CS (histological CS) by Japanese guidelines, were enrolled and examined. Clinical profile (age, sex, initial cardiac arrhythmias, and abnormal uptake of gallium-67 scintigraphy or 18F-fluorodeoxyglucose positron emission tomography in heart) was similar in both groups. Although clinical CS had better prognosis (P = 0.018) and outcome (all-cause death, appropriate defibrillator therapy, and heart transplantation; P = 0.008), multivariate Cox hazard analysis revealed that left ventricular ejection fraction (LVEF) and sustained ventricular tachycardia history were independently associated with outcome (P < 0.001 and P = 0.002, respectively), but not with the diagnosed CS category. Moreover, similar LVEF recovery after corticosteroid was observed in both groups with low LVEF (≤35%) at the 1-year follow-up period (P < 0.001). In clinical CS according to the Japanese guideline, prophylactic implantable-cardioverter-defibrillator and immunosuppressive therapy are important in patients with low LVEF or ventricular tachycardia history, similar to histological CS.
No takes yet. Share an insight, caveat, or question.
Kusano et al. (2021) conducted a cohort in Cardiac sarcoidosis (n=422). Clinical diagnosis of cardiac sarcoidosis (clinical CS) vs. Histologically diagnosed cardiac sarcoidosis (EMB-positive) was evaluated on Outcome (all-cause death, appropriate defibrillator therapy, and heart transplantation) (p=0.008). Clinical cardiac sarcoidosis had better unadjusted outcomes than histological disease, but LVEF and sustained ventricular tachycardia were independent predictors.
Synapse has enriched 10 related papers. Consider them for comparative context: